Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC cut its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 49.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,420 shares of the specialty pharmaceutical company's stock after selling 2,390 shares during the quarter. Moloney Securities Asset Management LLC's holdings in Jazz Pharmaceuticals were worth $257,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC increased its position in shares of Jazz Pharmaceuticals by 63.7% in the first quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company's stock worth $126,000 after acquiring an additional 395 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in Jazz Pharmaceuticals by 5.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,334 shares of the specialty pharmaceutical company's stock valued at $538,000 after purchasing an additional 232 shares during the period. Oppenheimer Asset Management Inc. raised its stake in Jazz Pharmaceuticals by 6.3% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 10,191 shares of the specialty pharmaceutical company's stock valued at $1,265,000 after purchasing an additional 603 shares during the period. Spire Wealth Management lifted its holdings in shares of Jazz Pharmaceuticals by 137.6% in the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after purchasing an additional 161 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its holdings in shares of Jazz Pharmaceuticals by 6.2% during the first quarter. Robeco Institutional Asset Management B.V. now owns 213,709 shares of the specialty pharmaceutical company's stock valued at $26,532,000 after buying an additional 12,405 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Analyst Ratings Changes

JAZZ has been the subject of a number of research reports. Truist Financial raised their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a "buy" rating in a research report on Thursday, August 28th. Morgan Stanley set a $183.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday. Weiss Ratings restated a "sell (d)" rating on shares of Jazz Pharmaceuticals in a report on Saturday. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Finally, Royal Bank Of Canada upped their target price on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a research report on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $180.00.

Jazz Pharmaceuticals Stock Up 0.3%

JAZZ opened at $138.53 on Friday. The firm has a market cap of $8.40 billion, a P/E ratio of -20.58, a price-to-earnings-growth ratio of 8.23 and a beta of 0.28. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The business has a 50 day moving average price of $130.44 and a 200 day moving average price of $117.00. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm's revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 3,500 shares of the firm's stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total value of $490,000.00. Following the sale, the director owned 408,826 shares of the company's stock, valued at $57,235,640. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.